Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
February 2014, Vol 5, No 1
February 2014, Vol 5, No 1
Obinutuzumab Outperforms Rituximab in Older Patients with CLL
By
Jayson Slotnik, JD, MPH
In the Literature
February 2014, Vol 5, No 1
The anti-CD20 antibody rituximab (Rituxan), combined with chemotherapy agents, had been shown to prolong overall survival (OS) in physically fit patients with previously untreated chronic lymphocytic leukemia (CLL), but not in those with comorbidities.
Read Article
Innovating Cancer Care to Improve Value: Health Care Innovation Awards Round Two
By
Craig Deligdish, MD
From the Editor
,
Value Peer-spectives
February 2014, Vol 5, No 1
The Patient Protection and Affordable Care Act (ACA) has been a major topic in the news of late. In addition to providing better healthcare and allowing the uninsured to obtain affordable insurance coverage, the ACA has provided funding for outcomes research and healthcare innovation.
Read Article
Hematologic Drug Pipeline Boasts Novel Approaches
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
February 2014, Vol 5, No 1
New Orleans, LA—Novel options for the treatment of patients with hematologic conditions are in the pharmaceutical pipeline, with many drugs showing promising results. Here is a look at key studies presented at the 2013 American Society of Hematology annual meeting.
Read Article
Enzalutamide Extends Survival in Previously Untreated Metastatic Prostate Cancer
By
Phoebe Starr
Genitourinary Cancers Symposium
February 2014, Vol 5, No 1
San Francisco, CA—Enzalutamide (Xtandi) prolonged survival and delayed radiographic progression of disease in men who had not received chemotherapy for metastatic castration-resistant prostate cancer (mCRPC).
Read Article
Novel CAR-T Therapy Shows Impressive Results in Aggressive Leukemia, Lymphoma
By
Phoebe Starr
Leukemia
,
Lymphoma
,
Personalized Medicine
February 2014, Vol 5, No 1
New Orleans, LA—Mounting evidence from several research centers shows that autologous T-cells genetically engineered with a chimeric antigen receptor-T (CAR-T; also called CTL019) achieve dramatic responses in patients with advanced leukemia and lymphoma who have exhausted all treatment options.
Read Article
ASCO Proposes New Reimbursement Model by Medicare for Cancer Care
By
Neil Canavan
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
The American Society of Clinical Oncology (ASCO) has proposed a radical new model for the reimbursement of oncology services under Medicare, with the new paradigm consisting of incentives for oncologists to emphasize quality rather than quantity of care as the greater good to the bottom line.
Read Article
Page 4 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma